Study 10 of 10Desmopressin literaturebiorxiv-preprint · Case report2026

AVP Deficiency Following 9-valent HPV Vaccination: A Case Report

This report highlights a rare case of AVP deficiency potentially linked to the 9-valent HPV vaccine, with complete resolution of symptoms following desmopressin treatment.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the desmopressin corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

This case report details a 30-year-old woman who developed arginine vasopressin (AVP) deficiency after receiving the 9-valent HPV vaccine. Following treatment with desmopressin, her symptoms resolved completely, and she remained symptom-free at 2.5 years of follow-up. MRI findings indicated pituitary stalk thickening and absence of the posterior pituitary bright spot.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Background Human papillomavirus (HPV) infection and associated diseases are a major global health burden, and the 9-valent HPV vaccine is widely used to reduce their incidence and mortality. This study reports the first documented case of arginine vasopressin (AVP) deficiency following 9-valent HPV vaccination, to highlight the need for clinical vigilance for potential post-vaccination adverse events. Case presentation: A 30-year-old Chinese woman developed symptoms after her first dose of the 9-valent HPV vaccine in July 2023. This report details her clinical data, laboratory results, MRI findings, treatment, and follow-up outcomes. One day after vaccination, the patient developed polyuria and severe thirst, with no prior history of head trauma, peripartum events, or endocrine disorders. Laboratory tests confirmed AVP deficiency, and brain MRI showed pituitary stalk thickening and absence of the posterior pituitary bright spot, consistent with infundibulo-neurohypophysitis. Following treatment with desmopressin, her symptoms resolved completely. At 2.5 years of follow-up, she remained on low-dose desmopressin without recurrence, and repeat MRI showed normalized pituitary morphology. Conclusion This is the first reported case of AVP deficiency potentially linked to 9-valent HPV vaccination. As HPV vaccine coverage expands, clinicians should remain alert to this rare immune-mediated complication.</p>

Elsewhere in the Desmopressin corpus

BRenal water handling at early stages of autosomal dominant polycystic kidney diseasebiorxiv-preprint · 2026 · Not reported in abstract.Human BPolyuria and Hypokalemia in an Adolescent: Deciphering the Dual Tubulopathy of Primary Sjögren’s Syndromebiorxiv-preprint · 2026 · Urine osmolality remained below 150 mOsm/kg after desmopressin.Human DAssessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.Lancet (London, England) · 2026—BClinical and diagnostic complexities of adipsic arginine vasopressin deficiency.JCEM case reports · 2026 · n=1 · 320 mOsm/kg plasma osmolality.Human BDiabetic ketoacidosis induced by long-acting growth hormone in a child without preexisting diabetes.JCEM case reports · 2026 · n=1 · Hemoglobin A1c was 5.7% (reference range, <5.7%)Human BPerioperative aspirin discontinuation prior to burr-hole drainage for chronic subdural hematoma: A European multicenter retrospective cohort study.Clinical neurology and neurosurgery · 2026 · n=140 · 6 acute (≤48 h) hemorrhagic events (5.8%) occurred: 4/19 (21.1%) with continuation versus 0/40 (0%) and 2/45 (4.4%) with short and long pause (three-group p = 0.005).Human